From June 2019 to April 2021, patients with metastatic cervical cancer who received ICI retreatment at the Cancer Center, Union Hospital, Huazhong University of Science and Technology, Wuhan, China, were enrolled in this study. The inclusion criteria were as follows: (1) pathologically confirmed squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix; (2) metastatic cervical cancer; (3) achieved complete response (CR), partial response (PR), or stable disease (SD) as the best clinical response to first-course immunotherapy; (4) received at least two cycles of retreatment with triplet combination therapy including PD-1 inhibitor, chemotherapy, and antiangiogenic agent; (5) had at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; and (6) Eastern Cooperative Oncology Group performance score of 1 or less. Patients who did not have the follow-up data were excluded from the analyses. Baseline clinicopathological data, including age, histology, initial stage, metastatic sites, primary surgery, lines of prior systemic treatment, and immunotherapy regimens, were retrieved from medical records.
This retrospective study was conducted in accordance with the principles embodied in the 1964 Declaration of Helsinki and was approved by the Ethics Committee of the Union Hospital of the Huazhong University of Science and Technology (20220023). Informed consent was obtained from all the participants or their legal guardians if the participants cannot write.
This retrospective study was conducted in accordance with the principles embodied in the 1964 Declaration of Helsinki and was approved by the Ethics Committee of the Union Hospital of the Huazhong University of Science and Technology (20220023). Informed consent was obtained from all the participants or their legal guardians if the participants cannot write.
